abs303.txt	objective		this	study	sought	to	define	the	role	of	first-line	platinum-baseddoublet	chemotherapy	in	older	patients	with	non-small	cell	lung	cancer	(nsclc)	materials	and	methods		we	analyzed	three	first-line	nsclc	trials		calgb	9730	calgb	30203		and	calgb	30801		which	tested	carboplatin	and	paclitaxel	carboplatin	and	gemcitabine		and	carboplatin	with	either	pemetrexed	orgemcitabine		respectively		overall	survival	was	the	primary	endpoint		age-basedcomparisons	with	a	cutpoint	of	65	years	were	performed	with	cox	proportionalhazards	models	with	adjustments	for	sex		tumor	histology		cancer	stage	chemotherapy		and	smoking	history	and	after	stratifying	by	performance	score	secondary	endpoints	were	grade	3-5	adverse	events		chemotherapy	cycles	completed	and	whether	toxicity	prompted	chemotherapy	discontinuation	results		730	patients	were	included		337	(46%)	were	65+	years	of	age		nostatistically	significant	difference	in	survival	was	observed	for	older	(≥65)versus	younger	patients	(hr	=	1	096		95%	ci	=	(0	94		1	28)		p	=	0	25)		a	trendemerged	with	increased	odds	of	a	grade	3-5	adverse	event	for	patients	≥65	yearsversus	<65	years	(or	=	1	52		95%	ci	=	(0	99		2	31)		p	=	0	05)		the	proportion	ofcompleted	chemotherapy	cycles	was	marginally	lower	in	older	patients(difference	=	-5%		95%	ci	=	(-9		0	2)		p	=	0	06)	for	those	≥65	years	versus<65	years		but	no	statistically	significant	difference	occurred	in	the	rate	ofchemotherapy	discontinuation	for	toxicity	(or	=	1	4		95%	ci	=	(0	85		2	19)	p	=	0	21)	for	patients	≥65	years	versus	<65	years		a	cutpoint	of	70	years	yieldedsimilar	results	conclusion		these	findings	support	carboplatin	doublet-based	chemotherapy	inselect	older	patients	with	advanced	nsclc	
